Gastrointestinal Cancer

SS 38 - GI 4 - Hepato-Pancreatic-Biliary

278 - Phase I Trial of Concurrent Stereotactic Body Radiation Therapy and Nelfinavir for Locally Advanced Borderline or Unresectable Pancreatic Cancer-Final Results

Wednesday, October 24
11:30 AM - 11:40 AM
Location: Room 206

Phase I Trial of Concurrent Stereotactic Body Radiation Therapy and Nelfinavir for Locally Advanced Borderline or Unresectable Pancreatic Cancer-Final Results
C. Lin1, V. Verma1, Q. Ly2, J. Schwarz2, J. Meza2, A. Sasson3, C. Are2, B. Kos2, and J. Grem2; 1Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE, 2University of Nebraska Medical Center, Omaha, NE, 3Stony Brook School of Medicine, Stony, NY

Purpose/Objective(s): The HIV protease inhibitor nelfinavir (NFV) displays notable radiosensitizing effects. There have been no studies evaluating combined stereotactic body radiation therapy (SBRT) and NFV for borderline/unresectable pancreatic cancer. The primary objective of this phase I trial (NCT01068327) was to determine the maximum tolerated SBRT/NFV dose, and secondarily evaluate outcomes.

Materials/Methods: Following initial imaging, pathologic confirmation, and staging laparoscopy, subjects initially received 3 3-week cycles of gemcitabine/leucovorin/fluorouracil; patients without radiologic progression received SBRT(5 fractions)/NFV. Dose escalation was as follows: 1) 25 Gy/625 mg BID x 3 wk; 2) 25 Gy/1250 mg BID x 3 wk; 3)30 Gy/1250 mg BID x 3 wk; 4) 35 Gy/1250 mg BID x 3 wk; 5) 35 Gy/1250 mg BID x 5wk; and 6) 40 Gy/1250 mg BID x 5 wk. Pancreaticoduodenectomy was performed thereafter if deemed resectable; if not, gemcitabine/leucovorin/fluorouracil was administered.

Results: Forty-six patients enrolled (10/2008-5/2013). Thirty-nine patients received SBRT/NFV on protocol; 16 (41%) experienced any grade ≥2 adverse event (AEs) during and 1 month after SBRT. There were 21, 11, and 2 instances of grades 2, 3, and 4 toxicities, respectively. Four instances of grade 3 events & both grade 4 events occurred in a single patient (started prior to SBRT/NFV) at the initial dose level. The final dose level was the maximum tolerated dose. Long-term follow up revealed that 5 patients had late gastrointestinal (GI) bleed (2, superior mesenteric artery pseudoaneusysm; 1, unknown; 1, negative esophagogastroduodenoscopy; 1, disease progression invading GI). The median overall survival was 14.4 months. Six (15%) patients experienced a local failure; the median local failure-free survival was not reached. Twenty-six had a distant failure as the first failure site (9, liver; 6, lung; 9, peritoneum). The median distant failure-free survival was 11 months, and the median all failure-free survival was 10 months. Twelve patients underwent pancreaticoduodenectomy; their median survival (19 months) was similar to those of unresected patients receiving 35-40 Gy (18 months) (p=0.924). As compared to those receiving 25-30 Gy (10 months), there was a trend towards higher survival in whom 35-40 Gy was delivered (p=0.083).

Conclusion: Concurrent SBRT (40 Gy)/NFV (1250 mg BID) for locally-advanced pancreatic cancer is safe and yields encouraging outcomes; a phase II study is currently ongoing. A close attention to SBRT plan & delivery is warranted to decrease the risk of late GI bleed.

Author Disclosure: C. Lin: Research Grant; Eppley Cancer center at UNMC, DHHS/NIH/NCI. To purchase a research drug; Eppley Cancer center at UNMC. Focus is on translational studies that address basic and clinical issues of importance to improving outcome of patients with pancreatic cancer. Role: Project Leader Title of the project: Novel Target(s) in the Radiosensitization of Pancreatic Cancer; DHHS/NIH/NCI. Vice chair of Research; University of Nebraska Medical Center. Colorectal track leader; ASCO 2018 annual meeting. V. Verma: None. Q. Ly: None. J. Schwarz: None. J. Meza: None. A. Sasson: None. C. Are: None.

Chi Lin, MD, PhD, MS

Disclosure:
Employment
University of Nebraska Medical Center: Associate Professor: Employee

Compensation
DHHS/NIH/NCI: Focus is on translational studies that address basic and clinical issues of importance to improving outcome of patients with pancreatic cancer. Role: Project Leader Title of the project: Novel Target(s) in the Radiosensitization of Pancreatic Cancer, Research Grants; Eppley Cancer center at UNMC: Research Grants, To purchase a research drug

Leadership
ASCO 2018 annual meeting: Colorectal track leader; University of Nebraska Medical Center,: Vice chair of Research

Biography:
CHI LIN, MD, PhD, Professor and Vice Chair of Research, Department of Radiation Oncology at University of Nebraska Medical Center (UNMC);
Associate Director for clinical and translational research mentored scholars program at UNMC;
UNMC Institutional Review Board and Scientific Review Committee member;
ASTRO CME-MOC committee member;
COG international outreach working group, representative to China;
NCCN Guidelines panel member for cancer in people living with HIV;
SANTRO newsletter editor;
A GI and pediatric radiation oncologist with special research interests in developing phase I and II trials;
Current research focus: the effects of SBRT with novel radiosensitizers on patients with pancreatic cancer and the effect of novel radioprotectors on patients with anal cancer.

Presentation(s):

Send Email for Chi Lin


Assets

278 - Phase I Trial of Concurrent Stereotactic Body Radiation Therapy and Nelfinavir for Locally Advanced Borderline or Unresectable Pancreatic Cancer-Final Results

Slides

Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Phase I Trial of Concurrent Stereotactic Body Radiation Therapy and Nelfinavir for Locally Advanced Borderline or Unresectable Pancreatic Cancer-Final Results